REVIEW ARTICLE


SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats



Om P. Sharma1, *, Werner Seiz2, Juergen Scheele2
1 Innoplexus Consulting Pvt. Ltd, 7th Floor, Midas Tower, Next to STPI Building, Phase 1, Hinjewadi Rajiv Gandhi Infotech Park, Hinjewadi, Pune, Maharashtra 411057, India
2 Innoplexus AG, Frankfurter Str. 27, Eschborn, 65760 Germany


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 592
Abstract HTML Views: 218
PDF Downloads: 202
Total Views/Downloads: 1012
Unique Statistics:

Full-Text HTML Views: 420
Abstract HTML Views: 135
PDF Downloads: 176
Total Views/Downloads: 731



Creative Commons License
© 2021 Sharma et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Innoplexus Consulting Pvt. Ltd, 7th Floor, Midas Tower, Next to STPI Building, Phase 1, Hinjewadi Rajiv Gandhi Infotech Park, Hinjewadi, Pune, Maharashtra411057, India; Tel: +91-9360083864; E-mail: om.sharma@innoplexus.com


Abstract

During the past two decades, the world has seen several known and novel zoonotic viruses and deadly bacterial diseases, such as West Nile Virus (1999 to 2002), Anthrax (2001), H1N1(2009), Ebola (2014), Zika Virus (2016), SARS-CoV (2002), MERS-CoV (2012) and SARS-CoV-2 in 2019. The current ongoing COVID-19 pandemic is completely unpredicted and it has hugely changed our health care systems, global economy and social lifestyles. SARS-CoV-2 is still under genetic evolution and getting mutated to escape our immune system and showing resistance against available therapies. In this current research work, we have examined all publicly available scientific literature to date to understand the genetic evaluation of coronavirus species and their transmission possibilities to humans. We have also explored recently reported mutations of concerns in viral spike glycoprotein. We then discussed various SARS-CoV-2 preclinical and clinical research breakthroughs and highlighted our limitations and readiness to combat this deadly disease. Based on our recent study, we have emphasized developing a global viral, fungi and microbes platform. It can help us to predict mutations on their genomic, structural and pathophysiological profile to better address early on future threats by such infectious agents.

Keywords: Coronavirus infections, SARS-CoV-2, COVID-19, Virus-host interaction, Prevention, Treatment strategies.